Safety and Efficacy Study of Neoadjuvant Radiohormonal Therapy for Oligometastatic Prostate Cancer: Protocol of an Open-Label, Dose-Escalation, Single-Centre Phase I/II Clinical Trial

Safety and Efficacy Study of Neoadjuvant Radiohormonal Therapy for Oligometastatic Prostate Cancer: Protocol of an Open-Label, Dose-Escalation, Single-Centre Phase I/II Clinical Trial

Background The optimal treatment for oligometastatic prostate cancer (OMPC) is still on its way. Accumulating evidence has proven the safety and feasibility of radical prostatectomy and local or metastasis-directed radiotherapy for oligometastatic patients. The aim of this trial is to demonstrate th...

Full description

Bibliographic Details
Main Authors: Xianzhi Zhao MD, Yu-Tian Xiao M.Med., Yue Yang MD, Yusheng Ye MD, Yifan Chang MD, Lingong Jiang MD, Md Eftekhar MD, Shancheng Ren MD, PhD, Huojun Zhang MD, PhD
Format: Article
Language:English
Published: SAGE Publishing 2022-08-01
Series:Cancer Control
Online Access:https://doi.org/10.1177/10732748221120462

Internet

https://doi.org/10.1177/10732748221120462

Similar Items